America’s Largest Generic Drug Supplier Aurobindo is in Deep with China’s Military
America’s largest generic drug supplier, Aurobindo, is riddled with safety and quality issues, including ties to overseas suppliers with links to China’s military.
America’s largest generic drug supplier, Aurobindo, is riddled with safety and quality issues, including ties to overseas suppliers with links to China’s military.
The roughly 485 million packages that come into the U.S. duty free via the de minimis loophole is “overwhelming” and that volume “makes it harder for us to police products for consumer safety,” James Joholske, director of the office of import surveillance at the U.S. Consumer Product and Safety Commission (CPSC) told the U.S. China Economic and Security Review Commission on March 1
According to expert testimony given by the witnesses, the crisis is being fueled by poor manufacturing practices that have led to recalls by foreign drug manufacturers, and the race to the bottom on generic drug prices that make it impossible for American generic drug makers to compete with subsidized competitors in India and China.
CPA’s report exposes that “Aurobindo does business with at least four suppliers that have ties to organizations under US sanctions for their connections to China’s military industry.”
The Biden administration must take swift action to close this loophole, it should issue nationwide withhold release order on all Chinese textiles, and Congress should pass legislation immediately.
Background De minimis is a regulatory loophole. It was morphed from a tiny customs administrative exception into a backdoor superhighway through our ports. The regulatory
Companies continue to invest in domestic solar thanks to all the new renewable energy tax credits. Without them, and tariffs, US solar would be China owned.
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
Notes from the recent Senate Foreign Relations Committee hearing on China. What the No. 2 at State said about China and U.S. supply chain risk.
A new report by the Government Accountability Office highlights the need for revamped trade deals. But missing from the discussion is the case for more local supply chains.